Q-Line Biotec IPO: The initial public offering of biochemistry reagents and consumables manufacturer Q-Line Biotec will open for subscription on Thursday, May 21. The price band has been set at ₹326 to ₹343 per share.
The company's shares will make their NSE SME debut on May 29.
Q-Line Biotec IPO: 10 key points to know
- Q-Line Biotec IPO subscription period: The initial share sale will be open from May 21 to May 25.
- Anchor investors' bidding: The anchor round bidding will occur on Wednesday, May 20.
- IPO offer structure: The ₹214.48 crore offer is exclusively a fresh issuance of 62.53 lakh shares. There is no offer for sale component.
- Objectives: The fresh issue proceeds will be utilised for working capital requirements, debt repayment and general corporate purposes.
- Q-Line Biotec IPO price band: The price range has been set at ₹326 to ₹343 per unit.
- Reservation: The company has set aside half of the net issue for qualified institutional buyers, 35% for retail investors and 15% for non-institutional investors.
- Q-Line Biotec IPO lot size: A lot consists of 400 shares. The minimum investor for an individual investor is two lots or 800 shares.
- Book-running lead manager and registrar: Hem Securities and Share India Capital Services Pvt Ltd are the book-running lead manager, while Purva Sharegistry is the registrar for the issue.
- Q-Line Biotec IPO allotment date: The basis of allotment is expected to be finalised on May 26.
- Q-Line Biotec IPO listing date: The share listing on the NSE and the BSE will occur on May 29.
NFP Sampoorna Foods IPO Day 3:Check subscription numbers, allotment date and steps
Q-Line Biotec IPO GMP
According to investorgain.com and media reports, the unlisted shares of Q-Line Biotec are trading at ₹454 per share, reflecting a grey market premium, or GMP, of 32.36% over the upper price band of ₹343.
Disclaimer: Grey Market Premium, or GMP, is an unofficial indicator of market sentiment toward an IPO. It is not regulated by the stock exchanges or SEBI. Upstox neither supports nor encourages grey market trading. Investors are advised to conduct their own research or consult an expert before making any investment decisions.